Novo Holdings portfolio company Clario to be acquired by Thermo Fisher Scientific

Novo Holdings portfolio company Clario, today announced a definitive agreement to be acquired by Thermo Fisher Scientific.

Clario integrates clinical trial endpoint data from devices, sites and patients enabling pharma and biotech customers to collect, manage and analyze clinical evidence digitally across every phase of drug development, supporting faster, more confident trial decisions. The company’s platform has supported approximately 70% of FDA drug approvals over the past decade.

Novo Holdings first invested in Clario in 2016, supporting the company alongside private equity firms, Astorg, Nordic Capital and Cinven.

Christoffer Søderberg, Managing Partner, Head of Principal Investments, Novo Holdings, commented: “We have been delighted to be a part of Clario’s journey since 2016, supporting the company’s strong organic growth and strategic acquisitions building a platform for sustained long-term growth. We commend the Clario team for their dedication to transforming the company into a leading provider of digital endpoints.”

Read the full announcement here.

Read more about Clario's journey with Novo Holdings, Astorg, Nordic Capital and Cinven here.

About Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Planetary Health Investments and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of EUR 142 billion.